Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $26.73, but opened at $18.94. Tyra Biosciences shares last traded at $20.4710, with a volume of 1,883,881 shares traded.
Analysts Set New Price Targets
A number of brokerages have commented on TYRA. Wolfe Research began coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They set a “peer perform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $45.00 price objective on shares of Tyra Biosciences in a report on Friday, September 4th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, August 5th. Piper Sandler reaffirmed an “overweight” rating and set a $56.00 target price on shares of Tyra Biosciences in a report on Tuesday. Finally, JonesTrading initiated coverage on shares of Tyra Biosciences in a research report on Wednesday, June 17th. They issued a “buy” rating and a $56.00 target price on the stock. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $48.22.
View Our Latest Stock Report on Tyra Biosciences
Tyra Biosciences Trading Down 20.0%
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, equities analysts expect that Tyra Biosciences, Inc. will post -2.74 EPS for the current fiscal year.
Institutional Investors Weigh In On Tyra Biosciences
A number of large investors have recently modified their holdings of TYRA. Jupiter Topco LLC purchased a new position in Tyra Biosciences during the second quarter valued at $139,161,000. Janus Henderson Group PLC grew its position in shares of Tyra Biosciences by 32.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock worth $148,867,000 after buying an additional 955,147 shares during the period. Commodore Capital LP grew its position in shares of Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after buying an additional 2,150,000 shares during the period. BlackRock Inc. bought a new position in shares of Tyra Biosciences in the 2nd quarter worth about $96,841,000. Finally, Farallon Capital Management LLC increased its stake in shares of Tyra Biosciences by 80.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock worth $54,337,000 after acquiring an additional 923,000 shares in the last quarter. Institutional investors own 84.14% of the company’s stock.
Tyra Biosciences Company Profile
Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.
The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.
Featured Articles
- Five stocks we like better than Tyra Biosciences
- 3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
- Gold.com’s Q4 Results Show Why This Stock Is More Than a Gold Bet
- Analog Devices Shows Why AI Is Not the Only Story Driving Chip Demand
- Cathie Wood Trimmed Palantir, But the Bigger Story Is Still Valuation
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
